BioLineRx (NASDAQ:BLRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

BioLineRx Stock Performance

BioLineRx stock opened at $0.41 on Wednesday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The firm has a market capitalization of $32.38 million, a P/E ratio of -0.53 and a beta of 1.46. BioLineRx has a 1-year low of $0.39 and a 1-year high of $1.93. The company’s 50-day moving average is $0.58 and its 200 day moving average is $0.64.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million. Research analysts forecast that BioLineRx will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. CVI Holdings LLC purchased a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned approximately 1.02% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.